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Identity 
Other names: BNIP3a, NIX 
HGNC (Hugo): BNIP3L 
Location: 8p21.2 
Local order: Cdca2 -Ebf2 - Ppp2r2a - Bnip3l - Pnma2 
- Dpysl2 - Adra1a 
DNA/RNA 
Description 
The gene spans 30122 bp and has 6 exons. The 
cytogenetic location of the gene is 8p21.2. The 
genomic coordinates are 8: 26240522 - 26270643. 
Transcription 




The protein is 219 amino acids, with a predicted MW 
of 23,8 kDa. The carboxy-terminal transmembrane 
domain of BNIP3L has been characterized by nuclear 
magnetic resonance and shown to form a kinked α-
helix (Bocharov et al., 2007). Structural bioinformatics  
 
analysis indicates that the rest of the protein is mo tly  
disordered. The LIR and the MER are predicted to form 
secondary structure (β-strand and α-helix, respectively) 
(Zhang et al., 2012). 
Expression 
BNIP3L is ubiquitously expressed. Northern blot 
hybridization reveals two transcripts of 1,6 kb and 3,9 
kb. These are expressed in heart, brain, placenta, lung
liver, skeletal muscle, kidney, and pancreas (Yasud et 
al., 1999). In another study, transcripts were identifi d 
in heart, brain, placenta, lung (low), liver, skeleta  
muscle (low), kidney, pancreas, spleen, thymus, 
prostate, testis, ovary, small intestine, colon, and 
peripheral blood leukocyte (Farooq et al., 2001). In the 
same study, there was also expression in cancer cell 
lines, including promyelocytic HL-60 (low), Hela S3 
(low), K562, lymphoblastic leukemia Molt-5, Burkitt's 
lymphoma-Raji, colorectal adenocarcinoma SW480, 
and lung carcinoma A549 cells. In another study, 1,4 
and 4,0 kb BNIP3L transcripts were found in primary 
hematopoietic cells and in cell lines, including K562, 
Hela, and Jurkat cells (Aerbajinai et al., 2003). BNIP3L 
is upregulated during erythroid maturation. 
BNIP3L protein can form an SDS-resistant dimer, 
which migrates at twice its predicted MW in SDS-
PAGE gels. BNIP3L dimerization is mediated through 
its transmembrane domain (Imazu et al., 1999). 
 
Organization of the human BNIP3L gene. The boxes represent exons, the line introns (not drawn to scale). Black areas represent 
coding sequence. 
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Functional domains of BNIP3L protein. LIR: LC3-interaction region (WVEL) (Schwarten et al., 2009; Novak et al., 2010); MER: minimal 
essential region (DMEKILLDAQHE) (Zhang et al., 2012); BH3-like: BCL2 homology 3-like domain (LKKSADWVSDW) (Yasuda et al., 
1999); TM: transmembrane domain. 
 
Localisation 
BNIP3L primarily localizes to the mitochondrial outer 
membrane (Chen et al., 1999; Imazu et al., 1999; 
Yasuda et al., 1999; Vande Velde et al., 2000).  
BNIP3L is oriented so that its amino terminus is in the 
cytoplasm, and its carboxy-terminal tail is in the 
mitochondrial intermembrane space.  
It also localizes to nuclear envelope, sarcoplasmic 
reticulum, and endoplasmic reticulum (Ohi et al., 1999; 
Diwan et al., 2009). 
Function 
BNIP3L and BNIP3 can cause cell death by several 
mechanisms, which are mediated by their BH3-like and 
transmembrane domains.  
In cardiomyocytes, mitochondria-targeted BNIP3L 
causes BAX/BAK-dependent mitochondrial outer 
membrane permeabilization, whereas ER/SR-targeted 
BNIP3L causes cyclophilin D-dependent opening of 
the MPT pore and mitochondrial depolarization (Chen 
et al., 2010).  
In tumor cells, BNIP3 expression is associated with 
opening of the MPT pore and autophagy (Vande Velde 
et al., 2000).  
Another property of BNIP3L and BNIP3 is their ability 
to mediate mitochondrial clearance during erythroid 
development (Schweers et al., 2007; Sandoval et al., 
2008) and in response to hypoxia (Zhang et al., 2008; 
Liu et al., 2012), respectively. BNIP3L mediates 
mitochondrial clearance in erythroid cells through its 
LIR (Schwarten et al., 2009; Novak et al., 2010) and 
MER (Zhang et al., 2012) domains. 
Homology 
BNIP3L is conserved from zebrafish to man. 
Mutations 
Note 




BNIP3L and the related protein BNIP3 (56% identical 
overall) are implicated in cancer progression.  
BNIP3 deregulation is more often implicated in cancer 
than BNIP3L, but the two proteins have a similar 
mechanism of action, so both are potentially relevant. 
BNIP3 and BNIP3L are reported to function as both 
tumor suppressors and oncogenes. This dual nature 
presumably reflects the roles of BNIP3 and BNIP3L in 
cell death pathways and autophagy; autophagy can 
promote cell survival. The frequent finding of BNIP3 
deregulation in cancer is likely related to its induction 
by hypoxia, and HIF1α signaling (Bruick, 2000).  
BNIP3L is also induced during hypoxia, by p53 (Fei et 
al., 2004). There are several mechanisms of BNIP3 and 
BNIP3L-induced cell death, which have recently been 
reviewed (Zhang and Ney, 2011).  
The role of BNIP3 and BNIP3L in cell death may 
explain their frequent deletion and silencing in tumors 
by promoter methylation (see below).  
By contrast, some advanced cancers express 
abnormally high levels of BNIP3 and BNIP3L. In these 
cases, the prosurvival role of these proteins in the 
induction of autophagy appears to dominate. 
Prostate cancer 
Note 
BNIP3 is expressed in 95% of prostate cancer samples 
and is either nuclear, cytoplasmic, or both. Cytoplasmic 
BNIP3 expression correlates with Gleason score, but 
not other clinicopathological parameters. By contrast, 
nuclear BNIP3 correlates with HIF1α and HIF2α 
expression (Shaida et al., 2008). BNIP3 promoter 
hypermethylation is present in 16% of prostate cancers, 
and BNIP3 expression is decreased in 21% of prostate 
cancers, but the two do not correlate (Murphy et al., 
2011).  
BNIP3L exhibits homozygous deletion in a prostate 
cancer cell line and primary prostate tumor (Liu et al., 
2008). Another study showed LOH of BNIP3L in 5% 
of prostate cancers, and a correlation with increasing 
disease stage (Cheng et al., 2012). 
Breast cancer 
Note 
BNIP3 expression in ductal carcinoma in situ is 
associated with higher grade, necrosis and invasive 
disease, whereas BNIP3L expression does not correlate 
with these parameters (Sowter et al., 2003). BNIP3L is 
not deregulated and infrequently mutated in ovarian 
and breast cancer (Lai et al., 2003). Loss of BNIP3  
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expression correlates with lymph node metastases and 
mitotic index, but not with the hypoxic response (Koop 
et al., 2009). Proteasome inhibition with Bortezomib 
blocks autophagy-mediated catabolism of long-lived 
proteins, and is associated with increased BNIP3 and 
cell death in breast cancer cell lines (Periyasamy-
Thandavan et al., 2010). On the other hand, resistance 
to the cytotoxic effects of TNFα in a subclone of breast 
cancer MCF-7 cells is associated with increased BNIP3 
and upregulation of the autophagy program (Moussay 
et al., 2011). Notably, hypoxic induction of BNIP3 and 
BNIP3L can cause breast cancer cell death and at the 
same time promote the survival of cancer-associated 
fibroblasts (Chiavarina et al., 2010). Thus, BNIP3 and 
BNIP3L may have compartment-specific effects on cell 
death and survival. 
Colorectal and gastric cancers 
Note 
BNIP3 promoter hypermethylation is found in 66% of 
primary colorectal and 49% of gastric cancers, but not 
in adjacent normal tissue (Murai et al., 2005b). 
Promoter hypermethylation but not gene mutation 
correlates with decreased BNIP3 expression. 
Pancreatic cancer 
Note 
BNIP3 is silenced by promoter hypermethylation in 
80% of pancreatic adenocarcinoma samples (Okami et 
al., 2004). BNIP3 expression is diminished in chronic 
pancreatitis and pancreatic ductal adenocarcinoma, and 
loss of BNIP3 expression correlates with decreased 
survival and chemotherapy resistance (Erkan et al., 
2005). Similarly, BNIP3L is reduced in liver 
metastases and the tumor invasion front compared with 
the primary pancreatic tumor, in an orthotopic SCID 
mouse model (Niedergethmann et al., 2007). 
Liver cancer 
Note 
Epigenetic silencing of BNIP3 and BNIP3L is 
associated with poor prognosis in hepatocellular 
carcinoma (Calvisi et al., 2007). In addition, a cSNP 
that causes premature termination of BNIP3L was 
reported in 40% of hepatocellular carcinoma cases 
(Wang et al., 2005). BNIP3 is a HIF1α target in HepG2 
tumor spheroids, and its expression is associated with 
increased autophagy and attenuation of apoptosis 
(Menrad et al., 2010). 
Lung cancer 
Note 
There is strong cytoplasmic expression of BNIP3 in 
38% of non-small cell lung cancer, which was 
associated with an aggressive phenotype and decreasd 
survival (Giatromanolaki et al., 2004). 
Malignant glioblastoma 
Note 
BNIP3 is expressed in hypoxic regions of glioblastoma 
multiforme (GBM), but is sequestered in the nucleus in 
~80% of tumors (Burton et al., 2006). In another study, 
BNIP3L appeared to act as a tumor suppressor in low-
grade astrocytomas, and as an oncogene in high grade 
GBM. In the latter case, BNIP3L expression correlated 
with NFκB activation through an unknown mechanism 
(Lu et al., 2012). 
Hematopoietic malignancy 
Note 
BNIP3 promoter hypermethylation is found in 15% of 
acute lymphocytic leukemia, 17% of acute 
myelogenous leukemia, and 21% of multiple myeloma. 
Promoter hypermethylation correlates with decreased 
BNIP3 expression (Murai et al., 2005a). BNIP3 
promoter hypermethylation correlates with decreased 
survival in multiple myeloma (Heller et al., 2008). 
Another study found BNIP3 promoter 
hypermethylation in 13% of newly diagnosed multiple 
myeloma but no association with prognosis (Braggio et 
al., 2010). 
Ischemic and hypertrophic heart 
disease 
Note 
Most of the evidence that BNIP3 and BNIP3L have a 
role in heart disease comes from animal models. BNIP3 
is regulated by hypoxia in cardiomyocytes through 
HIF1α binding sites in its promoter (Bruick, 2000). By 
contrast, BNIP3L is regulated by Gαq signaling in the 
setting of cardiac hypertrophy (Gálvez et al., 2006). 
Enforced expression of BNIP3L causes lethal 
cardiomyopathy in mice, whereas BNIP3L deficiency 
protects mice from Gαq-mediated and pressure 
overload cardiomyopathy (Yussman et al., 2002; 
Diwan et al., 2008). Further, BNIP3 deficiency protects 
against post-infarction ventricular remodeling (Diwan 
et al., 2007). Mice with combined deficiency of BNIP3 
and BNIP3L in the heart develop normally, but by 30 
weeks exhibit cardiac enlargement and decreased left 
ventricular ejection fraction (Dorn, 2010). 
Mitochondria in the hearts of these mice are increased 
in number and show variation in size and internal 
structure. Furthermore, young BNIP3/BNIP3L-
deficient mice subjected to aortic banding rapidly 
develop heart failure. 
Cerebral ischemia 
Note 
Animal models and in vitro studies also provide 
evidence that BNIP3 and to a lesser extent BNIP3L are 
a cause of neuronal cell death after hypoxia or 
denervation. BNIP3 is expressed in striatal and cortical 
neurons following transient focal ischemia in rats; 
prolonged BNIP3 expression in this setting is 
associated with delayed neuronal cell death (Althaus et 
al., 2006). BNIP3 knockdown inhibits nuclear 
translocation of EndoG and protects against hypoxia-
induced, caspase-independent, delayed neuronal cell 
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death (Zhang et al., 2007). Hypoxic mimetics cause 
BAX/BAK- and caspase-dependent neuronal precursor 
cell death in vitro, but also cause HIF1α and BNIP3 
upregulation. BNIP3 knockdown failed to prevent 
caspase activation, but inhibits nuclear translocati n of 
apoptosis-inducing factor and cell death (Walls et al., 
2009). Thus, BNIP3 mediates hypoxia-induced, 
caspase-independent neuronal cell death. Also, 
following neonatal nerve axotomy, BNIP3 and to a 
lesser extent BNIP3L, are induced in facial 
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